Dosing of antimicrobials in obesity: Difference between revisions
From IDWiki
(→) |
(→) |
||
(24 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
== Calculating Body Weight == |
== Calculating Body Weight == |
||
Weight-based dosing can use total body weight (TBW) in some instances, but often requires adjustments. |
|||
{| class="wikitable" |
{| class="wikitable" |
||
! Statistic !! Equation |
! Statistic !! Equation !! Notes |
||
|- |
|- |
||
| '''[https://www.mdcalc.com/body-mass-index-bmi-body-surface-area-bsa Body mass index]''' (BMI) (kg/m<sup>2</sup>) |
| '''[https://www.mdcalc.com/body-mass-index-bmi-body-surface-area-bsa Body mass index]''' (BMI) (kg/m<sup>2</sup>) |
||
| |
| <math>\frac{weight}{height^{2}}</math> |
||
| kg and m |
|||
| |
|||
|- |
|- |
||
| '''[https://www.mdcalc.com/body-mass-index-bmi-body-surface-area-bsa Body surface area]''' (BSA) (m<sup>2</sup>) |
| '''[https://www.mdcalc.com/body-mass-index-bmi-body-surface-area-bsa Body surface area]''' (BSA) (m<sup>2</sup>) |
||
| |
| <math>BSA = \sqrt{\frac{height \times weight}{3600}}</math> |
||
| kg and cm |
|||
| |
|||
|- |
|- |
||
| '''[https://www.mdcalc.com/ideal-body-weight-adjusted-body-weight Ideal body weight]''' (IBW) (kg) |
| rowspan=2 | '''[https://www.mdcalc.com/ideal-body-weight-adjusted-body-weight Ideal body weight]''' (IBW) (kg) |
||
| 50 + 2.3 |
| male: <math>50 + 2.3 \times \small{\text{(inches over 5 ft)}}</math> |
||
| |
| rowspan=2 | in inches |
||
| |
|- |
||
| female: <math>45.5 + 2.3 \times \small{\text{(inches over 5 ft)}}</math> |
|||
|- |
|- |
||
| '''[https://www.mdcalc.com/ideal-body-weight-adjusted-body-weight Adjusted body weight]''' (ABW) (kg) |
| '''[https://www.mdcalc.com/ideal-body-weight-adjusted-body-weight Adjusted body weight]''' (ABW) (kg) |
||
| |
| <math>IBW + C \times (TBW - IBW)</math> |
||
| C = 0.3 to 0.4 |
| C = 0.3 to 0.4 |
||
|- |
|- |
||
| '''Lean body weight''' (LBW) (kg) |
| rowspan=2 | '''Lean body weight''' (LBW) (kg) |
||
| 9270 |
| male: <math>\frac{9270 \times TBW}{6680} + 216 \times BMI</math> |
||
| rowspan=2 | |
|||
| 9270 × TBW / 8780 + 244 x BMI |
|||
| |
|||
|- |
|- |
||
| female: <math>\frac{9270 \times TBW}{8780} + 244 \times BMI</math> |
|||
| '''Fat-free weight''' (FFW) (kg) |
|||
| 0.00139 × (height, cm)<sup>2</sup> - 0.0801 × R + 0.187 × TBW + 39.83 |
|||
| 0.00151 × (height, cm)<sup>2</sup> - 0.0344 × R + 0.14 × TBW - (0.158 × age) + 20.387 |
|||
| R = resistance |
|||
|} |
|} |
||
== Calculating CrCl == |
|||
[https://globalrph.com/medcalcs/salazar-corcoran-calc/ Salazer-Cocoran equation] is more reliable in obesity but requires both height and weight. |
|||
== Antibiotics == |
== Antibiotics == |
||
=== |
=== β-lactams === |
||
==== Penicillins ==== |
|||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|- |
||
| [[Amoxicillin]] |
| [[Amoxicillin]] |
||
| 250-500 mg q8h |
|||
| 1 g PO q8h |
|||
| |
| |
||
| 1 g PO q8h |
|||
| No data |
|||
|- |
|- |
||
| [[Ampicillin]] |
| [[Ampicillin]] |
||
| 1-2 g q4-6h |
|||
| |
|||
| 2 g IV q4h |
| 2 g IV q4h |
||
| |
| |
||
Line 50: | Line 53: | ||
| |
| |
||
| 2 g IV q4h |
| 2 g IV q4h |
||
| |
| |
||
|- |
|- |
||
| [[Piperacillin-tazobactam]] |
| [[Piperacillin-tazobactam]] |
||
| 4.5 g IV |
| 4.5 g IV q8h (q6h for ''Pseudomonas'') |
||
| Prolonged infusion |
| Prolonged infusion |
||
| |
|||
| 18 g daily |
|||
|} |
|} |
||
=== Cephalosporins === |
==== Cephalosporins ==== |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|||
| [[Cefazolin]] |
|||
| 1-2 g IV q8h |
|||
| 2-3 g IV q6-8h |
|||
| No data; 12 g daily |
|||
|- |
|- |
||
| [[Cephalexin]] |
| [[Cephalexin]] |
||
| 500-1000 g PO qid |
| 500-1000 g PO qid |
||
| 1000 g PO qid |
| 1000 g PO qid |
||
| |
| |
||
|- |
|||
| [[Cefazolin]] |
|||
| 1-2 g IV q8h |
|||
| 2 g IV q6h once ≥120 kg |
|||
| |
|||
|- |
|- |
||
| [[Cefipime]] |
| [[Cefipime]] |
||
| 2 g IV q8h |
| 2 g IV q8h |
||
| 2 g IV q8h prolonged infusion |
| 2 g IV q8h prolonged infusion |
||
| |
|||
| 2 g IV q8h prolonged infusion |
|||
|- |
|- |
||
| [[Ceftazidime]] |
| [[Ceftazidime]] |
||
| 2 g IV q8h |
| 1-2 g IV q8h |
||
| 2 g IV q8h prolonged infusion |
|||
| 2 g IV q8h prolonged infusion |
| 2 g IV q8h prolonged infusion |
||
| |
|||
|- |
|- |
||
| [[Ceftazidime-avibactam]] |
| [[Ceftazidime-avibactam]] |
||
Line 90: | Line 93: | ||
| |
| |
||
| Usual dose |
| Usual dose |
||
| |
|||
|- |
|||
| [[Ceftaroline]] |
|||
| |
|||
| Consider q8h |
|||
| |
| |
||
|} |
|} |
||
=== Carbapenems === |
==== Carbapenems ==== |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|- |
||
| [[Doripenem]] |
| [[Doripenem]] |
||
Line 109: | Line 117: | ||
| [[Imipenem]] |
| [[Imipenem]] |
||
| |
| |
||
| Usual dose |
|||
| |
|||
| |
| |
||
|- |
|- |
||
| [[Meropenem]] |
| [[Meropenem]] |
||
| 500 mg q6h (1 g IV q8h for febrile neutropenia) |
|||
| |
|||
| Consider prolonged infusion |
| Consider prolonged infusion |
||
| |
| |
||
|} |
|} |
||
== Quinolones == |
=== Quinolones === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|||
| [[Ciprofloxacin]] |
|||
| 500-750 mg PO q12h or 400 mg IV q6-8h |
|||
| 400 mg IV q8h or 750 mg PO q12h |
|||
| |
|||
|- |
|||
| [[Levofloxacin]] |
|||
| 500-750 mg PO q24h |
|||
| Consider up to 1000 mg PO q24h |
|||
| |
|||
|- |
|||
| [[Moxifloxacin]] |
|||
| 400 mg q24h |
|||
| Usual dose |
|||
| |
|||
|} |
|} |
||
== |
=== Macrolides === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|} |
|} |
||
== |
=== Tetracyclines === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|} |
|} |
||
== |
=== Aminoglycosides === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|||
| [[Amikacin]] |
|||
| 15 mg/kg |
|||
| Use ABW<sub>0.4</sub> |
|||
| Use Hartford nomogram with a (halved) random level |
|||
|- |
|||
| [[Gentamicin]] |
|||
| 7 mg/kg |
|||
| Use ABW<sub>0.4</sub> |
|||
| Use Hartford nomogram with a random level |
|||
|- |
|||
| [[Tobramycin]] |
|||
| 7 mg/kg |
|||
| Use ABW<sub>0.4</sub> |
|||
| Use Hartford nomogram with a random level |
|||
|} |
|} |
||
== Others == |
=== Others === |
||
{| class="wikitable" |
{| class="wikitable" style="width:100%" |
||
! Drug !! Usual Dose !! Obesity !! |
! Drug !! Usual Dose !! Obesity !! Notes |
||
|- |
|||
| [[Aztreonam]] |
|||
| |
|||
| 2 g IV q6-8h |
|||
| |
|||
|- |
|||
| [[Colistin]] |
|||
| 5 mg CBA/kg IBW x1 loading (max 300 mg) followed by 5 mg/kg/day divided q8h |
|||
| Use IBW |
|||
| Max 360 mg daily (nephrotoxicity) |
|||
|- |
|||
| [[Polymyxin B]] |
|||
| |
|||
| Use ABW<sub>0/4</sub> |
|||
| Max 200 mg or 2 MU daily (toxicity) |
|||
|- |
|||
| [[Clindamycin]] |
|||
| 300-450 mg PO q6-8h<br/>600-900 mg IV q8h |
|||
| 600 mg IV q6h<br/>900 mg IV q8h<br/>450-600 mg PO q6h<br/>600-900 mg PO q8h |
|||
| Max 2700 mg daily, or 4800 mg daily IV if life-threatening |
|||
|- |
|||
| [[Dalbavancin]] |
|||
| |
|||
| Usual dose |
|||
| |
|||
|- |
|||
| [[Daptomycin]] |
|||
| 4-6 mg/kg q24h |
|||
| Use ABW<sub>0.4</sub> |
|||
| |
|||
|- |
|||
| [[Linezolid]] |
|||
| 600 mg PO/IV q12h |
|||
| Usual dose |
|||
| |
|||
|- |
|||
| [[Oritavancin]] |
|||
| |
|||
| Usual dose |
|||
| |
|||
|- |
|||
| [[TMP-SMX]] |
|||
| Up to 320 mg(TMP) PO q12h<br/>8-10 mg(TMP)/kg<sub>ABW</sub> in divided doses |
|||
| Consider ABW<sub>0.4</sub> when doing high dose |
|||
| |
|||
|- |
|||
| [[Telavancin]] |
|||
| |
|||
| Usual dose |
|||
| |
|||
|- |
|||
| [[Tigecycline]] |
|||
| |
|||
| Usual dose |
|||
| |
|||
|- |
|||
| [[Vancomycin]] |
|||
| 20-25 mg/kg load (max 2.5 g)<br />10-15 mg/kg q12h (maintenance) |
|||
| Use TBW; or 25-30 mg/kg load and 15 mg/kg q12h with ABW<sub>0.4</sub> |
|||
| |
|||
|} |
|} |
||
Line 146: | Line 244: | ||
* Comprehensive Guidance for Antibiotic Dosing in Obese Adults. ''Pharmacotherapy''. 2017;37(11):1415-1431. doi: [https://doi.org/10.1002/phar.2023 10.1002/phar.2023] |
* Comprehensive Guidance for Antibiotic Dosing in Obese Adults. ''Pharmacotherapy''. 2017;37(11):1415-1431. doi: [https://doi.org/10.1002/phar.2023 10.1002/phar.2023] |
||
[[Category: |
[[Category:Antimicrobials]] |
Latest revision as of 16:36, 8 June 2023
Calculating Body Weight
Weight-based dosing can use total body weight (TBW) in some instances, but often requires adjustments.
Statistic | Equation | Notes |
---|---|---|
Body mass index (BMI) (kg/m2) | kg and m | |
Body surface area (BSA) (m2) | kg and cm | |
Ideal body weight (IBW) (kg) | male: Failed to parse (unknown function "\small"): {\displaystyle 50 + 2.3 \times \small{\text{(inches over 5 ft)}}} | in inches |
female: Failed to parse (unknown function "\small"): {\displaystyle 45.5 + 2.3 \times \small{\text{(inches over 5 ft)}}} | ||
Adjusted body weight (ABW) (kg) | C = 0.3 to 0.4 | |
Lean body weight (LBW) (kg) | male: | |
female: |
Calculating CrCl
Salazer-Cocoran equation is more reliable in obesity but requires both height and weight.
Antibiotics
β-lactams
Penicillins
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Amoxicillin | 250-500 mg q8h | 1 g PO q8h | |
Ampicillin | 1-2 g q4-6h | 2 g IV q4h | |
Nafcillin | 2 g IV q4h | ||
Piperacillin-tazobactam | 4.5 g IV q8h (q6h for Pseudomonas) | Prolonged infusion |
Cephalosporins
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Cephalexin | 500-1000 g PO qid | 1000 g PO qid | |
Cefazolin | 1-2 g IV q8h | 2 g IV q6h once ≥120 kg | |
Cefipime | 2 g IV q8h | 2 g IV q8h prolonged infusion | |
Ceftazidime | 1-2 g IV q8h | 2 g IV q8h prolonged infusion | |
Ceftazidime-avibactam | Usual dose | ||
Ceftolozane-tazobactam | Usual dose | ||
Ceftaroline | Consider q8h |
Carbapenems
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Doripenem | Consider extended infusion | ||
Ertapenem | 1 g IV q24h | Usual dose | |
Imipenem | Usual dose | ||
Meropenem | 500 mg q6h (1 g IV q8h for febrile neutropenia) | Consider prolonged infusion |
Quinolones
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Ciprofloxacin | 500-750 mg PO q12h or 400 mg IV q6-8h | 400 mg IV q8h or 750 mg PO q12h | |
Levofloxacin | 500-750 mg PO q24h | Consider up to 1000 mg PO q24h | |
Moxifloxacin | 400 mg q24h | Usual dose |
Macrolides
Drug | Usual Dose | Obesity | Notes |
---|
Tetracyclines
Drug | Usual Dose | Obesity | Notes |
---|
Aminoglycosides
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Amikacin | 15 mg/kg | Use ABW0.4 | Use Hartford nomogram with a (halved) random level |
Gentamicin | 7 mg/kg | Use ABW0.4 | Use Hartford nomogram with a random level |
Tobramycin | 7 mg/kg | Use ABW0.4 | Use Hartford nomogram with a random level |
Others
Drug | Usual Dose | Obesity | Notes |
---|---|---|---|
Aztreonam | 2 g IV q6-8h | ||
Colistin | 5 mg CBA/kg IBW x1 loading (max 300 mg) followed by 5 mg/kg/day divided q8h | Use IBW | Max 360 mg daily (nephrotoxicity) |
Polymyxin B | Use ABW0/4 | Max 200 mg or 2 MU daily (toxicity) | |
Clindamycin | 300-450 mg PO q6-8h 600-900 mg IV q8h |
600 mg IV q6h 900 mg IV q8h 450-600 mg PO q6h 600-900 mg PO q8h |
Max 2700 mg daily, or 4800 mg daily IV if life-threatening |
Dalbavancin | Usual dose | ||
Daptomycin | 4-6 mg/kg q24h | Use ABW0.4 | |
Linezolid | 600 mg PO/IV q12h | Usual dose | |
Oritavancin | Usual dose | ||
TMP-SMX | Up to 320 mg(TMP) PO q12h 8-10 mg(TMP)/kgABW in divided doses |
Consider ABW0.4 when doing high dose | |
Telavancin | Usual dose | ||
Tigecycline | Usual dose | ||
Vancomycin | 20-25 mg/kg load (max 2.5 g) 10-15 mg/kg q12h (maintenance) |
Use TBW; or 25-30 mg/kg load and 15 mg/kg q12h with ABW0.4 |
Further Reading
- Comprehensive Guidance for Antibiotic Dosing in Obese Adults. Pharmacotherapy. 2017;37(11):1415-1431. doi: 10.1002/phar.2023